

Reverse Payment Patent Settlements: The Supreme Court Has Spoken

JUNE 18, 2013

On June 17, 2013, the Supreme Court issued its long-awaited decision in *FTC v. Actavis*. After years of litigation in the lower courts, this is the first time the Court weighed in on the antitrust treatment of “reverse payment” (sometimes also known as “pay-for-delay”) patent settlements between branded and generic pharmaceutical manufacturers. This panel discussion, sponsored by the ABA Section of Antitrust Law’s Health Care and Pharmaceuticals Committee, provides a first analysis of the Court’s landmark decision.

WilmerHale Partner Hartmut Schneider moderated this event.

[READ MORE ABOUT THE EVENT](#)

Speakers



Hartmut Schneider

PARTNER

✉ hartmut.schneider@wilmerhale.com

📍 WASHINGTON DC

📞 + 1 202 663 6948

Related Solutions

Antitrust and Competition

Antitrust Litigation

You May Be Interested In



Crypto Currently: Crypto Policy Updates

APRIL 4, 2024

WEBINAR



31st Annual Fordham Intellectual Property Law & Policy Conference

APRIL 4–5, 2024

SPEAKING ENGAGEMENT



CFTC 2023 Year in Review and a Look Forward Webinar

APRIL 9, 2024

WEBINAR

[VIEW ALL EVENTS](#)